## Abstract In 17 consecutive patients with Parkinson disease (PD), bilateral subthalamic nucleus (STN) stimulators were implanted during staged surgeries. The Unified Parkinson Disease Rating Scale (UPDRS) and the Dyskinesia Disability Scale were completed both __off__ and __on__ medication prior
Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease
✍ Scribed by Jasmine M. Henderson; Malcolm Pell; Dudley J. O'Sullivan; Elizabeth A. McCusker; Victor S.C. Fung; Philippa Hedges; Glenda M. Halliday
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 158 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0885-3185
- DOI
- 10.1002/mds.1261
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
This is the second neuropathological report detailing bilateral electrodes targeting the subthalamic nucleus (STN) in idiopathic Parkinson's disease (PD). The patient presented with unilateral tremor‐dominant parkinsonism. Bilateral STN stimulation was carried out 7 years later due to significant disease progression and severe motor fluctuations. The patient exhibited bilateral improvements in rigidity and bradykinesia both intraoperatively and postoperatively. The patient died 2 months later from aspiration pneumonia. Neuropathological examination confirmed both the diagnosis of PD and the electrode placements. The tip of the left electrode was located medially and posteriorly in the left STN and the tip of the right electrode entered the base of the thalamus/zona incerta immediately above the right STN. Tissue changes associated with the subthalamic electrode tracts included mild cell loss, astrogliosis, and some tissue vacuolation. Our postmortem analysis indicates little tissue damage associated with STN stimulation for PD. © 2001 Movement Disorder Society.
📜 SIMILAR VOLUMES
Early-onset parkinsonism with an onset before age 40 is quite hetereogenous in clinical, genetic, and pathologic aspects. Autosomal recessive juvenile parkinsonism (ARJP) is recognized as a distinct clinical entity characterized by early onset, sleep benefit, remarkable response to levodopa, and dop
## Abstract Subthalamic nucleus deep brain stimulation (STN‐DBS) is effective in advanced Parkinson's disease (PD), but its effects on the levodopa response are unclear. We studied the levodopa response after long‐term STN‐DBS, STN‐DBS efficacy and predictive value of preoperative levodopa response
## Abstract Deep brain stimulation of the subthalamic nuclei (STN) is a good therapeutic option to reduce dyskinesias and improve appendicular motor signs in well‐selected patients with advanced Parkinson's disease (PD). Concerns about long‐term adverse effects play an increasingly role in the deci
## Abstract We examined the impact of the subthalamic nuclei (STN) deep brain stimulation (DBS) on the health‐related quality of life (QoL) of patients with advanced Parkinson's disease (PD). Seventeen consecutive patients with refractory motor fluctuations and dyskinesia were included in the study
## Abstract The long‐term benefits of subthalamic nucleus deep brain stimulation (STN DBS) applied earlier in the disease course, before significant disability accumulates, remain to be determined. We developed a Markov state transition decision analytic model to compare effectiveness in quality‐ad